Michael Hart joins Ryah Medtech Team as VP Business Development


NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Ryah Medtech Inc. (“RYAH” or the “Company”), today announced that Michael Hart has joined the company as Vice-President, Business Development.

Focused on the global medical cannabis market, RYAH is a data aggregation and technology company that markets RYAH, the groundbreaking dose-measuring medicinal vaporizer used by patients for cannabinoids or dry herbs.

Far from being an outsider to cutting-edge companies in burgeoning industries, Mr. Hart comes to Ryah following a number of commercial mandates where he was instrumental to business growth through highly-successful consultative selling and joint venture development, i.e., not just racking up impressive sales figures but also bringing in numerous international corporations, both as customers and as partners.

Mr. Hart’s key mission will be to focus on opening the European and South American markets for Ryah, where the appreciation of medicinal cannabis is gaining rapid recognition and acceptance. He will be working out of London.

“Ryah has made incredible headway in the medical cannabis market in the course of the last year, launching its products in several States in the US and taking steps to gain accreditation with Health Canada, to name but a few milestones,” declared Mr. Hart. “It would be an understatement to say that it’s exciting to be joining the Ryah family at a time where medicinal cannabis is gaining worldwide attention and acceptance”, he went on to say.

Ryah’s newly appointed President and CEO, Gregory Wagner, had this to say about Mr. Hart’s nomination: “A highly-experienced business development executive with an impressive track record, Michael comes to us with a wealth of knowledge and quite an array of successes under his belt. He speaks several languages, shows excellent interpersonal skills and has vast marketing, business development, and consultative sales experience. He is also well-versed in financial forecasting and business planning and knows how to reach set targets”.

The RYAH vaporizer is a precision medicinal device that captures the amount of vapor a patient inhales. It creates a consistent and reliable vaporizing experience for patients by providing them with unprecedented temperature and dose control. The one-of-a-kind inhaler uses high-tech disposable medicinal cartridges that have embedded QR codes which serve to identify the cartridge’s contents, and comes accompanied with a highly popular mobile application.

The RYAH system provides users with the ability to track which cartridges work best for their specific needs and collects data for all parties who are in one way or another involved in the process, from the growers to pharmacies, laboratories and pharma companies. The data is integrated into a leading-edge big data AI platform that identifies correlations between cannabinoids and medical indications.

“I believe the Ryah technology will provide doctors and health-related institutions the confidence that their prescriptions will be administered in a safe and low risk manner while providing maximum results and comfort for their patients”, concluded Mr. Hart.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company, including: successfully being awarded a Health Canada accreditation; a Health Canada accreditation opening up markets to Ryah; Health Canada accreditation legitimizing the consumption of cannabis with Ryah; and the results users may receive from using Ryah; are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

For further information, please contact: 

Stephen Hart
Investor Relations
917-658-7878
invest@ryah.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b57b4b0f-3690-4873-9d0b-328a82975aee

Michael Hart, VP, Business Development, Ryah Medtech Inc.